Related Experiment Video
Updated: Jul 20, 2026
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Plasma cell leukemia (PCL): A report on 15 patients
Blood
|October 1, 1978
Summary
Plasma cell leukemia (PCL) presents differently than typical myeloma, resembling acute leukemia with organomegaly and pancytopenia. This aggressive blood cancer has a poor prognosis, with a median survival of only two months despite treatment.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Plasma cell leukemia (PCL) is a rare and aggressive hematologic malignancy.
- Understanding its distinct clinicopathologic features is crucial for diagnosis and management.
Observation:
- A detailed report on fifteen PCL patients reveals unique characteristics compared to multiple myeloma.
- PCL patients exhibit less bone disease but increased organomegaly, tissue infiltration, diffuse marrow involvement, and pancytopenia.
- One case of meningeal PCL highlights the central nervous system as a potential site of involvement.
Findings:
- Cytomorphologic analysis of PCL cells shows nuclear immaturity and asynchronous nuclear/cytoplasmic development.
- Despite treatment with cytotoxic agents effective in myeloma, PCL demonstrates a poor prognosis.
- The median survival for the reported PCL patients was a mere two months.
Implications:
- PCL requires distinct diagnostic and therapeutic strategies separate from typical myeloma.
- Further research into novel treatments is urgently needed to improve outcomes for PCL patients.
- Early recognition of PCL's unique features can aid in timely intervention and patient management.
